EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Antifibrotic therapy combined with pulmonary vasodilator therapy may improve survival in patients with pulmonary fibrosis and pulmonary hypertension: a retrospective cohort study

Christian Cardillo, Gerard J Criner iD, Shameek Gayen iD

Therapeutic Advances in Respiratory Disease · 2025

DOI: 10.1177/17534666251326743 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Christian Cardillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University Hospital, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Vasodilator Agents, Antifibrotic Agents, Pulmonary Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary fibrosis is a severe, progressive form of interstitial lung disease associated with increased morbidity and mortality. Pulmonary hypertension often accompanies severe pulmonary fibrosis and is also associated with worse outcomes. Antifibrotic therapy and pulmonary vasodilator therapy have demonstrated clinical benefits in pulmonary fibrosis and pulmonary hypertension, respectively. However, the benefit of combined antifibrotic and pulmonary vasodilator therapy in patients with both pulmonary fibrosis and pulmonary hypertension is less established.

Objectives

We aimed to determine the effectiveness of a combination pulmonary vasodilator and antifibrotic therapy with regard to transplant-free survival and six-minute walk distance improvement in patients with pulmonary fibrosis and pulmonary hypertension.

Design

This was a retrospective cohort study of patients with pulmonary fibrosis (idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema, and other fibrotic interstitial lung disease) and pulmonary hypertension diagnosed via right heart catheterization. Patients received antifibrotic therapy with or without pulmonary vasodilator therapy.

Methods

Patients who received combination antifibrotic therapy and pulmonary vasodilator therapy were compared to those prescribed antifibrotic therapy alone. Transplant-free survival and change in six-minute walk distance were compared between the two groups. Multivariable Cox regression was performed to determine predictors of transplant-free survival.

Results

Patients who received antifibrotic and pulmonary vasodilator therapy had significantly improved transplant-free survival (log rank p = 0.001). Treatment with antifibrotic and pulmonary vasodilator therapy was significantly and independently associated with reduced risk of death or lung transplantation (HR 0.24, 95% CI 0.06–0.93, p = 0.04). These patients had worse pulmonary hemodynamics than those receiving antifibrotic therapy alone.

Conclusion

We found a potential survival benefit when pulmonary vasodilator therapy was given in combination with antifibrotic therapy in patients with pulmonary fibrosis and pulmonary hypertension. This may be reflective of a pulmonary vascular phenotype among those with pulmonary fibrosis and pulmonary hypertension. Further trials are needed to better elucidate which patients benefit from combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryVasodilator AgentsAntifibrotic AgentsPulmonary FibrosisIdiopathic Pulmonary FibrosisHumansRetrospective StudiesMaleFemaleMiddle AgedDrug Therapy, CombinationWalk TestAgedLung TransplantationTime FactorsTreatment OutcomeExercise ToleranceRecovery of Function

Stichwörter der Autor:innen

antifibrotic therapypulmonary fibrosispulmonary hypertensionpulmonary vasodilator therapytransplant-free survival

Substanzen

Vasodilator AgentsAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University Hospital, Philadelphia, PA, USA.
  • Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University Hospital, 745 Parkinson Pavilion, 3401 N Broad Street, Philadelphia, PA 19140, USA.

ORCID-Profile: Gerard J Criner, Shameek Gayen

Zitieren

APA

Cardillo, C., Criner, G. J., & Gayen, S. (2025). Antifibrotic therapy combined with pulmonary vasodilator therapy may improve survival in patients with pulmonary fibrosis and pulmonary hypertension: a retrospective cohort study. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251326743

Vancouver

Cardillo C, Criner GJ, Gayen S. Antifibrotic therapy combined with pulmonary vasodilator therapy may improve survival in patients with pulmonary fibrosis and pulmonary hypertension: a retrospective cohort study. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251326743

BibTeX
@article{Cardillo2025,
  author = {Cardillo, Christian and Criner, Gerard J and Gayen, Shameek},
  title = {Antifibrotic therapy combined with pulmonary vasodilator therapy may improve survival in patients with pulmonary fibrosis and pulmonary hypertension: a retrospective cohort study},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  doi = {10.1177/17534666251326743}
}
Kostenlos starten →